Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

BMD Makes 2023 U.S. News & World Report "Best Law Firms" Edition

Client Alert
November 4, 2022

Brennan Manna & Diamond (BMD) is pleased to share the news that our firm is recognized among the “Best Law Firms” in the U.S. News & World Report 2023 edition in 14 practice areas.  “Best Law Firms” rankings are based on a rigorous evaluation process that includes the collection of client and lawyer evaluations, peer review from leading attorneys in their field and review of additional information provided by law firms as part of the formal submission process.    

This year, BMD is recognized in the metropolitan areas of Akron (Akron office), Cleveland (Cleveland office), and Fort Myers (Bonita Springs office) for professional excellence in: 

Metropolitan Tier 1
Akron

  • Health Care Law 
  • Litigation - Trusts & Estates 

Metropolitan Tier 2
Akron

  • Bankruptcy and Creditor Debtor Rights / Insolvency and Reorganization Law 
  • Corporate Law 
  • Litigation - Intellectual Property 
  • Litigation - Labor & Employment 
  • Trusts & Estates Law 

Cleveland 

  • Corporate Law 

Fort Myers (Bonita Springs)

  • Real Estate Law 

Metropolitan Tier 3 
Akron 

  • Closely Held Companies and Family Businesses Law 
  • Tax Law 
  • Trademark Law 

Cleveland 

  • Health Care Law 
  • Litigation - Labor & Employment 

Congratulations to our attorneys who are recognized for their professional excellence. 

Best Law Firm
Client Alert

Name, Image, and Likeness Agreements in Healthcare

November 14, 2025For example, some healthcare providers have begun to utilize "Name, Image, and Likeness" agreements to promote the brand they have created through their healthcare practice.  We have seen the most healthcare NIL activity with longevity and wellness providers, as well as orthopedics.Client Alert

Compounding GLP-1 Drugs - Recent Updates

November 13, 2025Recent guidance from the Ohio Board of Pharmacy (“BOP”) indicates that providers should generally use the FDA approved GLP-1 drug, rather than a non-FDA approved compounded version of the medication. Importantly, if a GLP-1 drug is commercially available, it cannot be copied through compounding. Currently, compounded copies of Tirzepatide and Semaglutide are not permitted.Client Alert

Top Compliance Risks for Ohio Med-Spas in 2025

November 11, 2025The Ohio Board of Pharmacy has increased inspections of med-spas holding Terminal Distributor of Dangerous Drugs (TDDD) licenses, with many facing enforcement actions in 2025. Common issues include purchasing from unlicensed distributors, improper drug storage, inadequate recordkeeping, and insufficient prescriber oversight. Understanding these risks and maintaining compliance can help protect your practice from penalties and license suspension.Client Alert

Pre and Postnuptial Agreements | Necessary, Maybe, What Happened to Forever?

November 7, 2025Both Florida and Ohio now allow clients to enter into a prenuptial or postnuptial agreement prior to marriage or after marriage (Ohio previously did not allow postnuptial agreements). Both documents have statutory guidelines that must be followed in terms of execution and financial disclosure.Client Alert

DHS Ends All Employment Authorization Auto-Extensions

October 29, 2025Effective October 30, 2025, DHS ends all automatic work authorization renewals. The 540-day extension applies only to renewals filed before this date, and there is no grace period for expired EADs filed on or after October 30. Employers must audit EADs, train staff, ensure I-9 compliance, and plan for work authorization gaps. Penalties for noncompliance can be severe.
Older posts